Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Xiao Zhou
Beth Israel Deaconess Medical Center, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Pinteon Therapeutics, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Pinteon Therapeutics, Inc., has licensed a specified subset of patents related to Pin1. Because the research results could be relevant in identifying potentially new Pin1 downstream targets would be useful in developing diagnostics and therapeutics, and the investigator’s significant financial interest could directly and significantly affect the design, conduct, or reporting of the PHS-funded research, BIDMC has determined that the private equity constitutes a financial conflict of interest with the research for this grant under applicable PHS regulations (45 C.F.R. §50.601 et seq.).
Function and Regulation of the Phosphorylation-Specific Prolyl Isomerase Pin1
During last 10 years of this grant, we have identified a unique enzyme called Pin1 as a key regulator of cell signaling in breast and other cancers. The current proposal will investigate the role of Pin1 in controlling the function of breast cancer stem cells,a small subset of breast cancer cells that might be responsible for tumor growth, metastases and resistance to therapies. These studies would lead to a better understanding of the basic mechanisms of breast cancer development and might help develop new and more effective therapies to overcome cancer resistance to current therapies.
Filed on September 17, 2014.
Tell us what you know about Xiao Zhou's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Xiao Zhou”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Xiao Zhou | Beth Israel Deaconess Medical Center | Conflict of Interest | Pinteon Therapeutics | Value cannot be readily determined |
| Xiao Zhou | Beth Israel Deaconess Medical Center | Conflict of Interest | Pinteon Therapeutics, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.